Across TCGA pan-cancer cohorts, MYL6B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MYL6B data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher MYL6B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MYL6B expression acts as an unfavorable survival marker.

KIRC and SKCM are the cancer types where MYL6B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.134	0.811	<.001	30	view →
SKCM	OS	Median	All	0.091	0.340	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: MYL6B tumor-vs-normal RNA expression · all MYL6B data types